The pharmacokinetics and in vitro cyclooxygenase selectivity of deracoxib in horses.

This study describes the absorption behavior and the selective anti-inflammatory effects of the drug deracoxib when orally administered to horses.

Objective and Methodology

• The goal of this study was to understand how deracoxib, a drug typically used for anti-inflammatory purposes, behaves within the body of a horse when orally administered.
• This process of drug absorption, distribution, metabolism, and excretion is called pharmacokinetics.
• The researchers used six healthy adult horses and gave them deracoxib orally at a dose of 2mg/kg.
• Blood samples were collected at various intervals before and after drug administration to trace the presence and concentration of the drug over time.
• The samples were analyzed using a method known as high pressure liquid chromatography with ultraviolet detection.

Results

• The results indicated that deracoxib has a long half-life of approximately 12.49 hours. The half-life of a drug is the time it takes for its concentration in the body to reduce by half. A longer half-life means the drug lasts longer in the body.
• The researchers also reported the maximum concentration of the drug reached in plasma was 0.54 µg/mL, achieved approximately 6.33 hours after administration.
• The bioavailability of the drug, which refers to how much of the administered drug reaches systemic circulation, could not be determined due to a lack of intravenous (IV) formulation for comparison.

Cyclooxygenase (COX) Selectivity of Deracoxib

• COX enzymes produce prostanoids, which are involved in processes like inflammation and pain. They are two types: COX-1 and COX-2.
• In this study, an in-vitro test was performed, which showed deracoxib was selective for COX-2. This means the drug inhibits COX-2 more than COX-1, reducing inflammation and associated pain.
• This selectivity was described by a COX-1/COX-2 ratio of 25.67 and 22.06 for the 50% and 80% inhibitory concentration (IC50 and IC80).

Potential Utility

• This study suggests that deracoxib, after oral administration, is absorbed in horses and could be used as an alternative treatment for conditions in horses requiring anti-inflammatory action.

This research is important for determining suitable drug options for pain and inflammation management in horses. It opens up possibilities for the use of deracoxib as a pharmacological option for equine healthcare.